Ad Age: Reckitt Benckiser seeking new creative to drive Mucinex business
NEW YORK — Reckitt Benckiser is seeking new creative behind its Mucinex brand, according to a report published in Ad Age Thursday.
Citing Kantar data, Ad Age reported RB placed $92 million behind Mucinex in 2012, when there was a strong and robust cough, cold and flu season helping to drive sales. Spending behind Mucinex in 2013 fell to $57 million.
RB CEO Rakesh Kapoor told analysts Wednesday that RB is "creating a new force in consumer health."
"We are allocating significant resources to consumer health, in terms of capabilities, R&D, brand equity investment and innovation, and we are seeing strong organic growth," he said. RB recently introduced Mucinex Allergy to store shelves.
Mylan announces launch of Xulane
PITTSBURGH — Mylan announced the launch of Xulane (norelgestromin/ethinyl estradiol transdermal system 150/35-mcg per day), the generic version of Ortho Evra (norelgestromin/ethinyl estradiol transdermal system 150/35-mcg per day) from Janssen Pharmaceuticals. The drug is used to prevent pregnancy in women who want to use a transdermal patch as a contraception method.
"Mylan is proud to continue expanding its portfolio of transdermal products through the launch of the first generic Ortho Evra Patch. Mylan’s Xulane (norelgestromin/ethinyl estradiol transdermal system 150/35-mcg per day), which provides women with a high quality, affordable treatment option, once again demonstrates Mylan’s commitment to bring to market difficult-to-develop and -manufacture medicines in support of our mission to expand access to high quality medicine," Heather Bresch, Mylan CEO, said.
Ortho Evra had sales in the United States of approximately $152.9 million for the 12 months ending Dec. 30, 2013, according to IMS Health.
Teva USA settles with Pfizer on generic Celebrex
JERUSALEM — Teva Pharmaceutical on Thursday announced that its U.S. subsidiary has entered into a settlement with Pfizer related to Teva’s generic version of Celebrex (celecoxib) 50-, 100-, 200- and 400-mg capsules in the United States.
Under the terms of the settlement, Teva may launch its generic versions in December, 2014, or earlier under certain circumstances. Teva has received tentative approval from the Food and Drug Administration for all strengths and believes that it is first-to-file on at least the 100-, 200- and 400-mg capsules.
Sales of Celebrex were $2.2 billion in the U.S. according to IMS data as of December, 2013.